Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-26-033104
Filing Date
2026-05-11
Accepted
2026-05-11 06:05:49
Documents
70
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q kzr-20260331.htm   iXBRL 10-Q 719274
2 EX-31.1 kzr-20260331xexx311.htm EX-31.1 10291
3 EX-31.2 kzr-20260331xexx312.htm EX-31.2 10219
4 EX-32.1 kzr-20260331xexx321.htm EX-32.1 5876
  Complete submission text file 0001628280-26-033104.txt   5357483

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kzr-20260331.xsd EX-101.SCH 46463
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kzr-20260331_cal.xml EX-101.CAL 55385
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kzr-20260331_def.xml EX-101.DEF 192237
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kzr-20260331_lab.xml EX-101.LAB 576585
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kzr-20260331_pre.xml EX-101.PRE 388261
74 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20260331_htm.xml XML 604906
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38542 | Film No.: 26960688
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)